Avid Bioservices Inc (CDMO)

[Robert C Jonson]

The point that I am trying to make is that reported median PFS values tend to vary quite a bit;

And that's a good point, thanks. It illustrates why the FDA is not (I think) relying on ORR and PFS, but MOS to make their drug approval decisions. Since there appears to be such variation in these subjective measurements, I'm not sure why we still list them as endpoints in drug trials.